Clinuvel Pharmaceuticals (ASX:CUV) successfully administered Scenesse, or afamelanotide, to a nine-year-old patient in Switzerland with severe symptoms of erythropoietic protoporphyria, a type of genetic disorder characterized by a deficiency in the ferrochelatase enzyme, according to a Friday filing with the Australian bourse.
Scenesse is approved for the prevention of phototoxicity, or sensitivity to light after exposure to a chemical substance, in adult patients with erythropoietic protoporphyria, the filing said.
Following a 2024 pharmacokinetic study that identified no safety concerns in all patients, Clinuvel intends to seek a label update approval in Europe later this year to cover adolescents, the filing added.
The company's shares slipped 2% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.